Physician profile
Michelle A Roda
NPI 1841233673
$2,965.45
in general payments reported to CMS, 2019-2025
13 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $2,026 · 2020: $897 · 2021: $42.39.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amgen INC. | $918.11 | 2019-2020 | |
| Teva Pharmaceuticals USA, INC. | $548.89 | 2019-2020 | |
| Allergan, INC. | $395.15 | 2019-2020 | |
| Supernus Pharmaceuticals, INC. | $367.51 | 2019-2020 | |
| Novartis Pharmaceuticals Corporation | $218.38 | 2019-2020 | |
| Lilly USA, LLC | $170.19 | 2019-2020 | |
| Lundbeck LLC | $66.38 | 2020-2021 | |
| Upsher-Smith Laboratories LLC | $64.92 | 2019-2020 | |
| Zyla Life Sciences, INC. | $62.03 | 2019 | |
| Merz North America, INC. | $43.46 | 2019 | |
| Assertio Therapeutics, INC. | $41.49 | 2019-2020 | |
| Amneal Pharmaceuticals LLC | $39.63 | 2019 | |
| Bausch Health US, LLC | $29.31 | 2019-2020 |
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Michelle Roda listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.